Human Genome Sciences ( HGSI ) said yesterday it's reviewing its strategic options , including a possible sale of the company. Human Genome rejected a $13/share bid from Glaxo last week and is likely hoping for a price in the high teens. Analysts are skeptical . 1 comment!
Trending Articles
More Pages to Explore .....